Despite the large number of biologics currently available for moderate-to-severe psoriasis,
poor adherence and persistence to therapy represent the main issues for both the clinical …

Introduction Interleukin 17 is a proinflammatory cytokine considered to play a significant role
in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 …

Introduction There is limited evidence to guide clinicians on the treatment of psoriasis with
biologics in patients with a history of malignancy who are often excluded from clinical trials …

Introduction Significant advances in psoriasis treatment have taken place since the
introduction of biologics. Tumor necrosis factor inhibitors were the first class of biologics …

Abstract Background and Objective The most recently approved biologics for moderate-to-
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Introduction There is limited and conflicting evidence over the real-world drug survival of
secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was …

Psoriasis is a systemic immunologic disorder associated with decreased quality of life and
numerous co-morbidities, including psoriatic arthritis and cardiovascular disease …

Secukinumab is a novel anti-IL17 biologic treatment approved for the treatment of psoriatic
arthritis (PsA). The purpose of the present study is to identify factors that can condition the …

Background Drug survival measures the rate and duration of adherence to a given
therapeutic agent and evaluates its long‐term effectiveness, safety, and real‐world utility …